SCHEDULE: FMR LLC Reports Stake in Soleno Therapeutics

FMR LLC, through its subsidiaries, has disclosed a beneficial ownership of 0.4% of Soleno Therapeutics Inc.'s common stock as of April 30, 2026.

Summary

• FMR LLC, along with its affiliates and subsidiaries, has filed a Schedule 13G indicating their beneficial ownership of Soleno Therapeutics Inc. common stock.
• The filing, dated April 30, 2026, reports that FMR LLC beneficially owns 193,013.61 shares, representing 0.4% of the class of securities.
• Abigail P. Johnson, a Director, Chairman, and CEO of FMR LLC, is also noted in relation to the ownership structure, with members of the Johnson family being predominant owners of FMR LLC's voting shares.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of passive investment and does not provide new operational or financial information about the company.

Positives

• FMR LLC's investment indicates confidence from a significant financial institution in Soleno Therapeutics Inc.
• The disclosure is a routine regulatory filing, suggesting no immediate negative events prompting the filing.

Negatives

• The reported ownership stake of 0.4% is relatively small, suggesting FMR LLC is a passive investor rather than an activist shareholder.
• The filing does not contain any specific operational or financial performance data for Soleno Therapeutics Inc.

Risks

• The filing does not explicitly mention any risks related to Soleno Therapeutics Inc.'s business operations or financial health.
• Potential risks for investors in Soleno Therapeutics Inc. could include those inherent in the biotechnology sector, such as clinical trial failures, regulatory hurdles, and market competition, though these are not detailed in this specific filing.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Soleno Therapeutics Inc.'s future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and asset managers like FMR LLC, indicating their investment activities. For a biotechnology company like Soleno Therapeutics Inc., such filings often signify a passive investment by a fund, rather than an active strategic partnership or control acquisition.

Stakeholder Impact

• Shareholders: The filing confirms FMR LLC as a shareholder, potentially adding stability to the shareholder base, though the stake is small.
• Management: The filing is a standard disclosure and does not directly impact management's operational decisions, but it confirms a large financial institution's passive interest.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• FMR LLC will continue to hold its shares in Soleno Therapeutics Inc. in the ordinary course of business.
• Soleno Therapeutics Inc. will continue its business operations, subject to market and regulatory conditions.

Key Dates

Keywords

Schedule 13G, FMR LLC, Soleno Therapeutics Inc., Beneficial Ownership, Common Stock, SEC Filing, Investment, Securities